Examining the technical indicators, the Moving Average Convergence Divergence (MACD) presents a contrasting picture: weekly data suggests a mildly bullish stance, whereas monthly readings indicate a mildly bearish trend. The Relative Strength Index (RSI) remains neutral on both weekly and monthly scales, showing no definitive momentum signal at present. Bollinger Bands reflect sideways movement on a weekly basis but lean mildly bearish monthly, indicating potential volatility compression in the short term with a cautious outlook over the longer horizon.
Our latest weekly pick is live! This Large Cap from Diamond & Gold Jewellery comes with clear entry and exit targets. See the detailed report with target price now!
- Clear entry/exit targets
- Target price revealed
- Detailed report available
Further technical analysis reveals that daily moving averages are positioned bearishly, reinforcing the short-term downtrend. The Know Sure Thing (KST) indicator aligns with this view, showing bearish signals on both weekly and monthly timeframes. Dow Theory readings offer a nuanced perspective, mildly bullish weekly but mildly bearish monthly, underscoring the mixed momentum across different periods. On-Balance Volume (OBV) data lacks a clear trend weekly but tilts mildly bearish monthly, suggesting volume patterns may be supporting the cautious price action.
From a market capitalisation standpoint, Lincoln Pharmaceuticals holds a grade of 4, reflecting its relative size within the Pharmaceuticals & Biotechnology sector. The Mojo Score currently stands at 37.0, with a recent adjustment in evaluation noted on 19 Nov 2025, following a prior grade change on 5 Aug 2025. The stock’s day change registers a modest decline of 0.54%, indicating subdued trading activity amid these technical shifts.
Looking at returns, Lincoln Pharmaceuticals shows a mixed performance relative to the Sensex benchmark. Over the past week and month, the stock’s returns of 0.96% and 0.94% respectively closely track the Sensex’s 0.96% and 0.86%. However, year-to-date figures reveal a divergence, with the stock down 33.12% compared to the Sensex’s positive 8.36%. Over longer horizons, the stock has outperformed the benchmark, delivering 73.54% over three years versus Sensex’s 37.31%, 127.01% over five years against 91.65%, and 235.48% over ten years compared to 232.28% for the Sensex.
Considering Lincoln Pharmaceuticals ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- Better options discovered
- Pharmaceuticals & Biotechnology + beyond scope
- Top-rated alternatives ready
In summary, Lincoln Pharmaceuticals is navigating a complex technical landscape characterised by a shift towards bearish momentum in several key indicators, while others remain neutral or mildly bullish in shorter timeframes. This mixed technical profile suggests that investors should closely monitor price action and indicator developments before making decisions. The stock’s historical outperformance over multi-year periods contrasts with recent subdued returns, highlighting the importance of a nuanced approach to evaluation within the Pharmaceuticals & Biotechnology sector.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
